4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-002470
Chief Scientific Officer sold 6,567 shares at $30.05 ($197,338)
- Chief Scientific Officer acquired 18,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-12-31 | Grant or award | −18,000 | 410,642 | D: show line 1 in the form | ||
| Bredt David Chief Scientific Officer | 2025-12-31 | Sale | −6,567 | $30.05 | $197,338 | 404,075 | D: show line 2 in the form |
| Open-market sales · 6,567 sh · avg $30.05 · $197,338 | |||||||
Loading xslF345X05/ownership.xml…